Here are Credit Suisse's top 3 biotech picks
Celgene : Target $144. Implied upside 33% . "We believe that CELG looks cheap relative to its growth after reviewing current and pipeline products.
from Biotech News
Celgene : Target $144. Implied upside 33% . "We believe that CELG looks cheap relative to its growth after reviewing current and pipeline products.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments